This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Fujifilm Corporation. Active years: 2021-2025.
Company Filing History:
Years Active: 2021-2025
Title: Kentaro Numajiri: Innovator in Liposome and Lipid Particle Technologies
Introduction
Kentaro Numajiri is a prominent inventor based in Ashigarakami-gun, Japan. He has made significant contributions to the field of pharmaceutical compositions, particularly in the development of liposome and lipid particle technologies. With a total of 2 patents, his work focuses on enhancing the efficacy of anticancer agents.
Latest Patents
Numajiri's latest patents include a liposome composition and a method for producing the same. The objective of this invention is to provide a liposome composition that contains a nucleic acid analog anticancer agent with an excellent leakage rate. The composition is characterized by specific ratios of lysophospholipid and nucleic acid analog anticancer agent to lipid. Another notable patent is for a lipid particle composition that contains panobinostat or a salt thereof, which exhibits a high bone marrow-targeting capability. This pharmaceutical composition aims to improve the delivery of therapeutic agents to targeted areas in the body.
Career Highlights
Kentaro Numajiri is associated with Fujifilm Corporation, where he applies his expertise in innovative pharmaceutical technologies. His work has contributed to advancements in drug delivery systems, particularly in oncology.
Collaborations
Numajiri has collaborated with notable colleagues, including Mikinaga Mori and Takahiro Sekiguchi. Their combined efforts have furthered research and development in the field of liposome and lipid particle technologies.
Conclusion
Kentaro Numajiri's innovative work in liposome and lipid particle technologies has the potential to significantly impact cancer treatment. His contributions to the field are marked by his patents and collaborations, showcasing his commitment to advancing pharmaceutical science.